Lineage to Present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 & the H.C. Wainwright...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, today announced that Brian M.
Culley, Chief Executive Officer, will be presenting at the Raymond
James 42nd Annual Institutional Investors conference on March 1,
2021 at 11:40am Eastern Time / 8:40am Pacific Time. Mr. Culley will
also be presenting at the H.C. Wainwright Global Life Sciences
Conference, being held virtually March 9-10, 2021.
Interested investors can access the live and archived webcasts
on the Events and Presentations section of Lineage’s website.
Additional videos are available on the Media page of the Lineage
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
version on businesswire.com: https://www.businesswire.com/news/home/20210223005043/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(firstname.lastname@example.org) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
David.email@example.com (212) 845-4242